BioSpace News Archive

ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171, the proprietary molecule which forms the basis of ECT-001 Cell Therapy.

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2021) - Driven by the high demand in Israel, BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) reports that its Q4 sales orders for VINIA®, the Company’s proprietary red grape cell dietary supplement and functional food, have exceeded the earlier Q4 sales order forecast for the quarter.

Derek Cody, M.D., a Crystal Clinic plastic and reconstructive surgeon, has performed the area’s first functional free-tissue transfer procedure to treat facial paralysis caused by damage to the nerves that control facial movement.

OncoDNA, a theranostic and genomic company specializing in precision oncology, has announced that it has signed a subcontract service agreement with HalioDx’s U.S.-based CLIA-certified laboratory located in Richmond, Virginia.

CORRECTING and REPLACING Syros to Present at 39 th Annual J.P. Morgan Healthcare Conference CORRECTION...by Syros Pharmaceuticals CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

According to the report titled ‘Global Nerve Repair and Regeneration Market Size study, by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) and Regional Forecasts 2020-2027’, available with Market Study Report LLC, global nerve repair and regeneration market was worth USD 5.72 billion in 2019 and is anticipated to record a 9.15% CAGR during 2020-2027.

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the 2021 BioConnect Virtual Conference hosted by H.C. Wainwright.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Zenocutuzumab (Zeno) for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancers) that have progressed on

-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9001-treated participants showed an increase in NSAA total score compared to placebo at 48 weeks; however, the study did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to placebo at 48 weeks post-treatment --

The double-blind, placebo-controlled investigator-initiated CYstic fibrosis PHage study at Yale (CYPHY) will assess the safety and efficacy of phage therapy YPT-01 against chronic Pseudomonas aeruginosa infections